复发性流产人群中未可视化妊娠丢失的患病率、原因及影响
该回顾性队列研究纳入1859例复发性流产患者,分为纯未可视化妊娠丢失组(14.7%)、纯可视化妊娠丢失组(31.8%)和混合组(53.5%)。控制母亲年龄和随访时间后,未可视化妊娠丢失数(OR 0.77,CI 0.68-0.88)和可视化妊娠丢失数(OR 0.75,CI 0.64-0.86)均为后续活产的显著预测因素(P<0.001)。
要点
- 纯未可视化妊娠丢失、纯可视化妊娠丢失和混合组的患病率分别为14.7%、31.8%和53.5%。
- 每增加一次未可视化妊娠丢失,活产几率降低23%(OR 0.77,CI 0.68-0.88)。
- 每增加一次可视化妊娠丢失,活产几率降低25%(OR 0.75,CI 0.64-0.86)。
核心结论
- 既往未可视化妊娠丢失数量是复发性流产患者后续活产的显著预测因素。
- 未可视化妊娠丢失似乎以与临床流产相同的方式影响未来活产,支持将其纳入复发性流产定义。
研究设计与样本
- 回顾性队列研究,纳入2012年1月至2021年3月期间就诊于三级医疗中心专门复发性流产门诊的1981例患者,其中1859例符合纳入标准并纳入分析。
- 复发性流产定义为20周妊娠前≥2次妊娠丢失。
- 患者评估包括父母核型分析、抗磷脂抗体筛查、子宫腔评估(子宫输卵管造影或宫腔镜)、母体促甲状腺激素检测和血清血红蛋白A1C检测;其他检查仅在指征时进行,如遗传性血栓形成倾向检测、血清催乳素、口服葡萄糖耐量试验和子宫内膜活检。
- 患者分为三组:纯未可视化妊娠丢失组、纯可视化妊娠丢失组和混合组。
- 统计分析采用Wilcoxon秩和检验(连续变量)和Fisher精确检验(分类变量),显著性定义为P值<0.05;采用逻辑回归模型确定未可视化妊娠丢失和可视化妊娠丢失数量对初次复发性流产门诊就诊后任何活产的影响。
主要发现
- 纯未可视化妊娠丢失、纯可视化妊娠丢失和混合组的患病率分别为14.7%(274/1859)、31.8%(591/1859)和53.5%(994/1859)。
- 经子宫输卵管造影或宫腔镜诊断的获得性和先天性子宫异常的患病率在三组间存在显著差异(纯未可视化妊娠丢失组16.8% vs 纯可视化妊娠丢失组23.7% vs 混合组20.7%,P=0.05)。
- 三组间其他复发性流产检查结果或基线人口学特征无显著差异。
- 控制初次复发性流产门诊就诊时母亲年龄和随访时间的逻辑回归模型显示,未可视化妊娠丢失数量(OR 0.77,CI 0.68-0.88)和可视化妊娠丢失数量(OR 0.75,CI 0.64-0.86)是初次复发性流产门诊就诊后后续活产的强预测因素(P<0.001)。
- 每增加一次未可视化妊娠丢失和可视化妊娠丢失,活产几率分别降低23%和25%。
关键数值与推荐
- 未可视化妊娠丢失数量对后续活产的OR为0.77(CI 0.68-0.88),P<0.001。
- 可视化妊娠丢失数量对后续活产的OR为0.75(CI 0.64-0.86),P<0.001。
- 获得性和先天性子宫异常患病率:纯未可视化妊娠丢失组16.8% vs 纯可视化妊娠丢失组23.7% vs 混合组20.7%,P=0.05。
临床怎么用
- 作者认为未可视化妊娠丢失似乎以与临床流产相同的方式影响未来活产,支持将其纳入复发性流产定义。
- 原文未据此给出推荐。
局限性
- 本研究可能受其回顾性设计限制。
- 部分数据包括家庭妊娠试验和产科病史基于患者自我报告,可能高估未可视化妊娠丢失的真实患病率。
- 另一局限性是分析时缺乏所有患者的活产数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Does the occurrence of non-visualized pregnancy loss (NVPL) affect future reproductive outcomes in patients with recurrent pregnancy loss (RPL)? SUMMARY ANSWER: The number of previous NVPLs is a significant predictor of subsequent live birth in patients with RPL. WHAT IS KNOWN ALREADY: The number of preceding miscarriages is a strong indicator for future reproductive outcomes. However, NVPL particularly has been sparsely addressed in previous literature. STUDY DESIGN, SIZE, DURATION: We performed a retrospective cohort study of 1981 patients attending a specialized recurrent pregnancy loss clinic (RPL) from January 2012 to March 2021. A total of 1859 patients met the inclusion criteria of the study and were included in the analysis. PARTICIPANTS/MATERIALS, SETTING, METHODS: Patients with a history of RPL, defined as ≥2 pregnancy losses before 20 weeks gestation, who attended a specialized RPL clinic in a tertiary care center were included. Patients' evaluation included parental karyotyping, antiphospholipid antibodies screening, uterine cavity assessment with hysterosalpingography (HSG) or hysteroscopy, maternal thyroid stimulating hormone (TSH) testing, and serum hemoglobin A1C testing. Other investigations were performed only when indicated such as testing for inherited thrombophilias, serum prolactin, oral glucose tolerance test, and endometrial biopsy. Patients were divided into three groups; patients who experienced NVPLs only (pure NVPLs group), patients with only visualized pregnancy losses (pure VPLs group), and patients with history of both NVPLs and VPLs (mixed group). Statistical analysis was performed using Wilcoxon rank-sum tests for continuous variables and Fisher's exact tests for categorical variables. Significance was detected when P values <0.05. A logistic regression model was used to determine the impact of NVPLs and VPLs numbers on any live birth subsequent to the initial RPL clinic visit. MAIN RESULTS AND THE ROLE OF CHANCE: The prevalence of patients with pure NVPLs, pure VPLs, and mixed losses was 14.7% (274/1859), 31.8% (591/1859), and 53.5% (994/1859), respectively. The prevalence of acquired and congenital uterine anomalies diagnosed by HSG or hysteroscopy was significantly different between pure NVPLs, pure VPLs, and mixed groups (16.8% versus 23.7% versus. 20.7%, respectively P = 0.05). There were no significant differences in the results of other RPL investigations or baseline demographics between the three groups. A logistic regression model controlling for maternal age at the initial RPL clinic visit and the follow-up duration showed that the numbers of NVPLs (odds ratio (OR): 0.77, CI: 0.68-0.88) and VPLs (OR: 0.75, CI: 0.64-0.86) are strong predictors for subsequent live births after the initial RPL clinic visit (P < 0.001). The odds of having a live birth decreased by 23% and 25% with each additional NVPL and VPL, respectively. LIMITATIONS, REASONS FOR CAUTION: This study may be limited by its retrospective design. Some of our data, including home pregnancy tests and obstetric history, are based on patient self-reporting, which could have overstated the true prevalence of NVPLs. Another limitation is the lack of available live birth data for all patients at the time of the analysis. WIDER IMPLICATIONS OF THE FINDINGS: To our knowledge, this is the first study to examine and analyze the reproductive outcomes of patients with pure NVPLs in a substantial cohort of patients with RPL. NVPLs seem to affect future live births the same way as clinical miscarriages, which supports their inclusion in RPL definitions. STUDY FUNDING/COMPETING INTEREST(S): This study was supported in part by Canadian Institute Heath Grant (CIHR): Reference Number/W11-179912 and Women's Health Research Institute (WHRI), Vancouver, BC, Canada. M.A.B: Research grants from Canadian Institute for Health Research (CIHR) and Ferring Pharmaceutical. M.A.B. is on the advisory board for AbbVie and Baxter. TRIAL REGISTRATION NUMBER: N/A.
引用
- Bedaiwy MA, Fayek B, Yang EC, et al. Prevalence, causes, and impact of non-visualized pregnancy losses in a recurrent pregnancy loss population. Hum Reprod. 2023. PMID: 36881694. doi:10.1093/humrep/dead040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。